Get the Stockscreener App
25.73
7.21%
-2.00
After Hours:
25.70
-0.03
-0.12%
Greenwich Lifesciences Inc stock is traded at $25.73, with a volume of 128.65K.
It is down -7.21% in the last 24 hours and down -4.10% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$27.73
Open:
$27.5
24h Volume:
128.65K
Relative Volume:
0.26
Market Cap:
$356.48M
Revenue:
-
Net Income/Loss:
$-19.48M
P/E Ratio:
-17.57
EPS:
-1.4641
Net Cash Flow:
$-8.59M
1W Performance:
+2.14%
1M Performance:
-4.10%
6M Performance:
+108.34%
1Y Performance:
+114.95%
1-Day Range:
$25.68
$28.00
1-Week Range:
$24.76
$30.12
52-Week Range:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
25.73 | 384.19M | 0 | -19.48M | -8.59M | -1.4641 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Aug Update: Will Greenwich LifeSciences Inc stock benefit from M A2025 Winners & Losers & Community Consensus Trade Signals - baoquankhu1.vn
Analyst Upgrade: Is Lavoro Limiteds growth already priced inJuly 2025 Highlights & Low Risk Growth Stock Ideas - baoquankhu1.vn
HC Wainwright Issues Positive Forecast for GLSI Earnings - Defense World
Valuation Update: Can Greenwich LifeSciences Inc expand into new marketsJuly 2025 Momentum & Weekly Momentum Stock Picks - baoquankhu1.vn
Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7% – Time to Sell? - Defense World
Greenwich LifeSciences: Strengthened Liquidity and Robust GP2 Data Support Reiterated Buy and $50 Target - TipRanks
Discipline and Rules-Based Execution in GLSI Response - Stock Traders Daily
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock By Investing.com - Investing.com Nigeria
Will Greenwich LifeSciences Inc. benefit from current market trendsTrade Signal Summary & Free Real-Time Volume Trigger Notifications - mfd.ru
Greenwich LifeSciences reports $12.5 million cash balance - Investing.com
Greenwich LifeSciences reports $12.5 million cash balance By Investing.com - Investing.com Nigeria
Greenwich LifeSciences provides update on Flamingo-01 cash burn rate and financing strategy - marketscreener.com
Greenwich LifeSciences, Inc. Reports Positive Financial Updates and Progress on FLAMINGO-01 Phase III Trial - Quiver Quantitative
Greenwich Lifesciences Provides Update On Flamingo-01 Cash Burn Rate And Financing Strategy - TradingView
Biotech Greenwich LifeSciences raises $7M in 3 weeks for breast cancer trial - Stock Titan
FDA Approval Boosts Greenwich LifeSciences Stock Sharply - timothysykes.com
Treasury Yields: Will Greenwich LifeSciences Inc benefit from current market trendsMarket Volume Report & Low Risk Entry Point Tips - baoquankhu1.vn
Greenwich: GP2 Vaccine MilestoneWhat FDA Manufacturing Approval Means For Investors - Seeking Alpha
Insiders of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) must be frustrated after market cap dropped US$50m since recent purchases - Yahoo Finance
Behavioral Patterns of GLSI and Institutional Flows - Stock Traders Daily
FDA approves commercial GP2 lot for Greenwich’s breast cancer trial By Investing.com - Investing.com Canada
Why Did Greenwich Lifesciences Stock Soar Pre-Market Today? - Menafn.com
Why Did Greenwich LifeSciences Stock Soar Pre-Market Today? - Asianet Newsable
GLSI Stock Surges Pre-Market On Clearing FDA Manufacturing Step For Its Breast Cancer Trial - Stocktwits
Greenwich LifeSciences stock soars after FDA approves commercial GP2 in trial - Investing.com Canada
Greenwich gets FDA nod for commercially made product candidate - Seeking Alpha
Greenwich LifeSciences surges as FDA clears supplies for breast cancer trial - TradingView
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01 - The Manila Times
FDA approves first GP2 batch for breast cancer trial, 200,000 doses - Stock Titan
Head to Head Contrast: Greenwich LifeSciences (NASDAQ:GLSI) & Vertex Pharmaceuticals (NASDAQ:VRTX) - Defense World
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 1,800 Shares of Stock - MarketBeat
Greenwich LifeSciences CEO Patel buys $53,694 in GLSI stock By Investing.com - Investing.com Canada
Greenwich LifeSciences stockholders reelect board and auditor - MSN
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush - Baystreet.ca
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 2,900 Shares of Stock - MarketBeat
Greenwich LifeSciences CEO Patel buys $79,866 in GLSI stock By Investing.com - Investing.com South Africa
Greenwich LifeSciences CEO Patel buys $79,866 in GLSI stock - Investing.com
Greenwich LifeSciences (GLSI) Price Target Increased by 13.10% to 48.45 - Nasdaq
Chart Watch: Will Greenwich LifeSciences Inc stock benefit from commodity pricesJuly 2025 Reactions & Entry Point Confirmation Signals - Bộ Nội Vụ
Technical Analysis: Is Greenwich LifeSciences Inc stock ready for breakoutTrade Exit Summary & Reliable Price Action Trade Plans - Bộ Nội Vụ
Why is GLSI stock rising today? - MSN
HER2-Positive Breast Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx - The Globe and Mail
Will Greenwich LifeSciences Inc. stock outperform growth indexesJuly 2025 Selloffs & Accurate Intraday Trading Signals - Улправда
Why Greenwich LifeSciences Inc. stock is a must watch in 2025Volume Weighted Average Price & Smart Beta Strategies That Actually Work - Улправда
How $594B in Precision Tech is Cracking the Metastatic Cancer Code - The Globe and Mail
Snehal Patel Buys Handful Of Shares In Greenwich LifeSciences - simplywall.st
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 4,300 Shares - Defense World
Will Greenwich LifeSciences Inc. stock benefit from upcoming earnings reports2026 world cup usa national team group stage star players transition play group prediction preview - ulpravda.ru
A US$74m drop in the market cap of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is not what insiders like to see after purchasing shares recently - simplywall.st
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 4,300 Shares of Stock - MarketBeat
Head-To-Head Analysis: Greenwich LifeSciences (NASDAQ:GLSI) vs. Avalon GloboCare (NASDAQ:ALBT) - Defense World
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):